Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a submission to the FDA.
Regenxbio’s headquarters in Rockville, Md.Regenxbio
By Adam Feuerstein and Jason Mast
May 14, 2026
Adam Feuerstein
adam.feuerstein@statnews.com
Regenxbio said Thursday that its Duchenne muscular dystrophy gene therapy met the bar in a pivotal study, and it’s aiming for FDA…
Though two serious side effects muddied the results, CEO Curran Simpson expressed optimism about a clearance and claimed FDA…
Regenxbio plans to submit its Duchenne gene therapy for FDA approval, just a month after it said that regulators wanted to see…
The FDA will reconsider approving Regenxbio's experimental gene therapy for a deadly and rare childhood brain disorder it…
The agency took another step toward clearing a backlog of Makary-era rejections that appeared to contradict earlier agreements…
Regenxbio plans to resubmit its Hunter syndrome gene therapy RGX-121 after the FDA reversed course, saying existing data are…
